Ionis Pharmaceuticals, Inc. (IONS) is up 3.03% today as buyers respond to ongoing momentum after the company received EU approval for its RNA-targeted therapy Tryngolza (olezarsen) to treat severe ...
Ionis Pharmaceuticals, Inc. (IONS) dropped 3.27% today as technical momentum remained overwhelmingly negative, with clear selling pressure dominating the session. The bearish structure is ...
Ionis Pharmaceuticals, Inc. (IONS) rebounded 4.21% in a sharp intraday bounce, driven by technical momentum after an extended selloff. The move looks limited, with the stock still trading below ...
Ionis Pharmaceuticals (IONS) dropped 4.74% after investors reacted to data showing its therapy pelacarsen did not meet the primary endpoint in the HORIZON cardiovascular trial, even as positive ...
Ionis Pharmaceuticals, Inc. (IONS) dropped 3.93% as heavy selling momentum and oversold conditions led price action lower. The down move is supported by the persistent bearish structure, with IONS ...
Ionis Pharmaceuticals, Inc. (IONS) fell 5.77% today as persistent technical selling pressure dominated the session. The move is reinforced by the stock remaining below all key moving averages and ...
Ionis Pharmaceuticals, Inc. (IONS) fell 3.45% after reporting a second-quarter adjusted loss and disappointing clinical trial results for its lead pipeline candidate. The move is reinforced by ...
Ionis Pharmaceuticals, Inc. (IONS) fell 8.6% after the company reported that its late-stage Phase 3 clinical trial for Wainua, developed with AstraZeneca, failed to reduce cardiovascular deaths ...
Ionis Pharmaceuticals (IONS) stock is trading at $79.98 after a modest move lower on the day. Shares are slipping but remain positioned above medium- and long-term ...
The Trump administration is trying to expand its most-favored-nation drug pricing plan beyond the largest pharmaceutical groups through a Medicaid pilot program. The effort is meeting hesitation ...